Dexcom sales climb 30% in Q1, beating estimates on The Street

Dexcom (NSDQ:DXCM) beat expectations on Wall Street yesterday with its first-quarter results, topping analysts’ sales estimates by $12.3 million.

The San Diego, Calif.-based company posted a net loss of -$24.2 million, or -28¢, on sales of $184.4 million for the three months ended March 31, for bottom-line growth of 42% on sales growth of 30% compared with the same period last year.

Get the full story at our sister site, Drug Delivery Business News.

The post Dexcom sales climb 30% in Q1, beating estimates on The Street appeared first on MassDevice.

from MassDevice https://ift.tt/2riunVZ